20-valent pneumococcal conjugate vaccine
Antibody Deficiency
University of Alabama at BirminghamvaccinePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Antibody Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
HUMAN IMMUNOGLOBULINS Grifols Therapeutics LLC | Phase 3 | B |
HUMAN IMMUNE GLOBULIN G Rutgers, The State University of New Jersey | Phase 1 | NR |
Same molecule, other indications
20-valent pneumococcal conjugate vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →